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Fibroblast growth factor 21 (FGF21) is a metabolic
hormone with pleiotropic effects on regulating
glucose and lipid homeostasis and insulin sensitivity.
However, the mechanisms underlying the metabolic
actions of FGF21 remain unknown. Here we show
that the insulin-sensitizing adipokine adiponectin is
a downstream effector of FGF21. Treatments with
FGF21 enhanced both expression and secretion of
adiponectin in adipocytes, thereby increasing serum
levels of adiponectin in mice. Adiponectin knockout
mice were refractory to several therapeutic benefits
of FGF21, including alleviation of obesity-associated
hyperglycemia, hypertriglyceridemia, insulin resis-
tance, and hepatic steatosis. Furthermore, the
effects of FGF21 on attenuation of obesity-induced
impairment in insulin signaling in liver and skeletal
muscle were abrogated in adiponectin knockout
mice, whereas FGF21-mediated activation of ERK1/
ERK2 in adipose tissues remained unaffected. There-
fore, adiponectin couples FGF21 actions in local
adipocytes to liver and skeletal muscle, thereby
mediating the systemic effects of FGF21 on energy
metabolism and insulin sensitivity.
INTRODUCTION
Fibroblast growth factor 21 (FGF21) is a member of the endo-
crine FGF subfamily with multiple metabolic functions (Potthoff
et al., 2012; Kharitonenkov et al., 2005). Unlike the prototypical
members of the FGF family, FGF21 does not have mitogenic
activities but acts as an important regulator of energy homeosta-
sis, glucose and lipid metabolism, and insulin sensitivity. Physi-
ologically, FGF21 plays a key role in mediating the metabolic
responses to fasting or starvation, including fatty acid oxidation
and ketogenesis (Badman et al., 2007; Potthoff et al., 2009; Ina-
gaki et al., 2007). Pharmacologically, recombinant FGF21 thera-Cpies have been shown to counteract obesity and its related
metabolic disorders in both rodents and nonhuman primates,
including reduction of adiposity and alleviation of hyperglycemia,
hyperinsulinemia, insulin resistance, dyslipidemia, and fatty liver
disease (Xu et al., 2009b; Coskun et al., 2008; Kharitonenkov
et al., 2007). Furthermore, FGF21 is the downstream target of
both peroxisome proliferator-activated receptor-alpha (PPARa)
and PPARg, and a growing body of evidence suggest that the
glucose-lowering and insulin-sensitizing effects of the PPARg
agonists (thiazolidinediones, TZDs) and the therapeutic benefits
of the PPARa agonists (fenofibrates) on lipid profiles are medi-
ated in part by induction of FGF21 (Dutchak et al., 2012; Li
et al., 2012).
While the liver is the predominant site for FGF21 production,
adipocytes are a main target of FGF21 actions (Ding et al.,
2012; Ve´niant et al., 2012; Adams et al., 2013; Chen et al.,
2011b). In white adipocytes, FGF21 stimulates glucose uptake
in an insulin-independent manner (Kharitonenkov et al., 2005),
modulates lipolysis (Chen et al., 2011b), enhances mitochondrial
oxidative capacity (Chau et al., 2010), and potentiates PPARg
activity (Dutchak et al., 2012). There is also good evidence that
FGF21 is involved in the thermogenic functions of brown adipo-
cytes (Hondares et al., 2011; Potthoff et al., 2012). Furthermore,
FGF21 is expressed and secreted in both white and brown adi-
pocytes (Hondares et al., 2011; Zhang et al., 2008), and the
autocrine actions of FGF21 in adipocytes play an obligatory
role in mediating the metabolic benefits of PPARg on glucose
homeostasis and peripheral insulin sensitivity, by forming a
feed-forward loop with this nuclear receptor (Dutchak et al.,
2012). Notably, lipodystrophic mice with reduced adipose tissue
are refractory to both acute and chronic effects of systemic
FGF21 administration in decreasing blood glucose and in
increasing insulin sensitivity, whereas the FGF21 responsive-
ness was completely restored after transplantation of white
adipose tissue into lipodystrophic mice, thus confirming that
adipose tissue is a predominant site conferring the antidiabetic
activities of FGF21 (Ve´niant et al., 2012). However, it is currently
unclear how FGF21 controls systemic metabolic homeostasis
via its actions in adipocytes.
Adiponectin, an adipokine predominantly secreted from
adipocytes, bears many functional similarities with FGF21 inell Metabolism 17, 779–789, May 7, 2013 ª2013 Elsevier Inc. 779
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Figure 1. The Effects of FGF21 on Expression and Secretion of
Adiponectin in Mouse Adipocytes
Stromal vascular cells isolated from epididymal fat pads were differentiated
into mature adipocytes, which were then treated with 1 mg/ml recombinant
mouse FGF21 (rmFGF21) or vehicle control for various periods.
(A) Total adiponectin concentrations in serum-free medium, expressed as the
fold over vehicle control in each time point.
(B) The relative mRNA abundance of the FGF21 gene as determined by real-
time PCR.
(C) Representative autoradiograph of 35S-labeled adiponectin at various
stages during a pulse-chase study. Cell lysates (CL) and conditioned medium
(CM) at different time intervals after the chase were collected and subjected to
immunoprecipitation using rabbit anti-mouse adiponectin IgG. The graph in
the right panel represents the percentage of adiponectin released into the
culture media.
Data are presented as mean ± SEM. *p < 0.05 and **p < 0.01 versus vehicle
control. n = 5 in each group. See also Table S2.
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Adiponectin as a Downstream Effector of FGF21regulating glucose and lipid metabolism and insulin sensitivity. In
different animal models of obesity and diabetes, adiponectin
decreases hyperglycemia, alleviates glucose intolerance and
insulin resistance, improves lipid profiles, and ameliorates fatty
liver disorders (Yamauchi et al., 2001; Xu et al., 2003; Berg
et al., 2001). Adiponectin controls systemic glucose and lipid
homeostasis via its endocrine actions on several major meta-
bolic organs, including liver and skeletal muscle (Kadowaki
et al., 2006). Furthermore, adiponectin is also a downstream
effector of PPARg and is an essential mediator for many thera-
peutic benefits of the PPARg agonists TZDs, including insulin
sensitization and vascular protection (Nawrocki et al., 2006;
Chang et al., 2010; Kubota et al., 2006).
In this study, we investigated the reciprocal relationship
between FGF21 and adiponectin in both primary adipocytes
and mice and tested our hypothesis that adiponectin may
mediate the pleiotropic metabolic benefits of FGF21 by com-
paring both acute and chronic effects of recombinant mouse
FGF21 (rmFGF21) in adiponectin knockout (ADNKO) mice and
wild-type (WT) controls with dietary or genetic obesity.
RESULTS
FGF21 Increases Both Adiponectin Expression and
Secretion in Adipocytes
FGF21 and adiponectin exhibit similar beneficial effects on
metabolism and insulin sensitivity. To elucidate the relationship
between these two metabolic regulators, we first investigated
the effects of FGF21 on adiponectin expression and secretion.
Treatment of mouse adipocytes with rmFGF21 caused a signifi-
cant elevation of adiponectin secretion in a time-dependent
manner (Figure 1A). At 1, 6, 12, and 24 hr after treatment, total
adiponectin concentrations in the conditioned medium were
1.6- ± 0.3-, 2.1- ± 0.3-, 2.4- ± 0.4-, and 2.6- ± 0.5-fold higher
than the vehicle control group, respectively. On the other hand,
a progressive increase in adiponectin messenger RNA (mRNA)
expression occurred from 6 hr after FGF21 treatment (Figure 1B).
Pulse-chase experiment with 35S methionine demonstrated that
FGF21 markedly enhanced the secretion rate of newly synthe-
sized adiponectin from adipocytes (Figure 1C), suggesting that
FGF21 increases both the gene transcription and secretion of
adiponectin.
As FGF21 has been shown to activate PPARg in adipo-
cytes (Dutchak et al., 2012), we next investigated the role
of this transcription factor in FGF21-induced adiponectin pro-
duction. Pretreatment of mouse adipocytes with the PPARg
antagonist GW9662 partially abrogated FGF21-induced secre-
tion of adiponectin (Figure 2A) and also significantly decreased
FGF21-induced adiponectin mRNA expression (Figure 2B).
Likewise, the magnitude of FGF21-stimulated adiponectin
secretion and gene expression in fat explants isolated from
PPARg+/ mice was much lower than those from wild-type
littermates (Figures 2C and 2D). Furthermore, the protein
expression of Ero1-La and DsbA-L, both of which are molecu-
lar chaperones involved in adiponectin oligomerization and
secretion (Wang et al., 2007; Liu et al., 2008), was significantly
elevated by FGF21 treatments, whereas such an effect of
FGF21 was attenuated by GW9662 or PPARg haplodeficiency
(Figures 2E and 2F).780 Cell Metabolism 17, 779–789, May 7, 2013 ª2013 Elsevier Inc.Adiponectin Production in Adipocytes Is Induced by
Autocrine Actions of FGF21
In addition to hepatocytes, FGF21 is also expressed in both
mouse and human adipocytes (Zhang et al., 2008). Adipocyte-
derived FGF21 has been implicated in the insulin-sensitizing
activity of the PPARg agonists (Dutchak et al., 2012). We next
investigated whether endogenous FGF21 in adipocytes modu-
lates adiponectin production in an autocrine manner. FGF21-
null adipocytes exhibited amodest decrease in both adiponectin
mRNA expression (Figure 3A) and its protein concentration in
the conditioned medium compared to WT controls (Figure 3B).
Furthermore, the amplitude of rosiglitazone-induced adiponec-
tin expression and secretion was markedly attenuated in
FGF21-null adipocytes (Figures 3A and 3B). Likewise, the
stimulatory effects of rosiglitazone on adiponectin production
in the explants of human visceral fat pads were also diminished
by coincubation with a neutralizing antibody against FGF21
(Figure 3C).
FGF21 Acts as an Upstream Regulator of Adiponectin
Production in Mice
Consistent with our in vitro findings above, the serum level of
total adiponectin in FGF21 KO mice was significantly lower
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Figure 3. The Roles of Endogenous FGF21 in the PPARg Agonist-
Induced Adiponectin Production in Adipocytes
(A and B) Mature adipocytes derived from stromal vascular cells isolated from
FGF21 KO and WT mice were treated with rosiglitazone (1.0 mM) for 6 hr in a
serum-free DMEM medium. The relative mRNA abundances of the adipo-
nectin gene (A) and adiponectin protein concentration (B) in the conditioned
medium were analyzed in Figure 1.
(C) Adiponectin protein concentration in the conditioned medium of human
adipose tissue explants treated with rosiglitazone (1.0 mM) in the presence
of rabbit anti human FGF21 IgG (5 mg/ml) or nonimmune IgG as a control
for 6 hr.
Data are presented as the mean ± SEM. *p < 0.05, **p < 0.01. n = 5 in each
group.
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Figure 2. The Role of PPARg in FGF21-Induced Expression and
Secretion of Adiponectin
Mouse primary adipocytes differentiated from stromal vascular cells were
pretreated with GW9662 (10.0 mM) for 1 hr, followed by incubation with FGF21
(1 mg/ml) for another 6 hr. Adiponectin concentration in the conditioned
medium (A) and relative adiponectin mRNA abundance (B) were analyzed as in
Figure 1. (C) and (D) show the comparison of adiponectin concentration in the
conditioned medium and adiponectin mRNA abundance between PPARg+/
and PPARg+/+ mouse adipocytes treated with or without FGF21 (1 mg/ml) for
6 hr. (E) and (F) show the representative immunoblots for the protein expres-
sion levels of Ero1-La and DsbA-L in mouse adipocytes treated as in (A), or
PPARg+/ and PPARg+/+ mouse adipocytes as in (C). Data are presented as
mean ± SEM. *p < 0.05, **p < 0.01. n = 5–6. See also Table S2.
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Adiponectin as a Downstream Effector of FGF21than that in age-matched wild-type mice on standard chow.
Notably, high-fat diet (HFD) feeding for 4 weeks increased serum
levels of both FGF21 and adiponectin in WT mice, whereas such
a HFD-induced elevation in adiponectin was largely abrogated in
FGF21 KOmice (Figure 4A). At 35 weeks after feeding with HFD,
plasma levels of adiponectin in wild-type mice was markedly
decreased as compared to mice fed standard chow (Figure 4A).
Furthermore, themagnitude of decrease in circulating adiponec-
tin in HFD-fed FGF21 knockout mice was much greater than that
in HFD-fed wild-typemice, demonstrating that the lack of FGF21
leads to a further reduction of adiponectin. Acute injection of
recombinant FGF21 led to a significant elevation of circulatingCell Metabolism 17, 779–789, May 7, 2013 ª2013 Elsevier Inc. 781
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Figure 4. FGF21 Induces Adiponectin Pro-
duction in Mice
(A) Serum levels of adiponectin in FGF21 KO and
WT mice on chow and HFD for 4 weeks and
35 weeks.
(B) The acute effect of single rmFGF21 injection
(2 mg/kg and 0.1 mg/kg) on serum levels of
adiponectin in 10-week-old C57/BL6 mice.
(C) The circulating levels of FGF21 at various time
points after mice receiving chronic delivery of
rmFGF21 with subcutaneously implanted osmotic
pumps.
(D) Effects of chronic administration with rmFGF21
on serum levels of adiponectin.
(E) The distribution of the three oligomeric com-
plexes of adiponectin as determined by gel filtra-
tion analysis. Serum samples were collected
from the mice after treatment with rmFGF21 for
4 weeks.
Data are presented as mean ± SEM. *p < 0.05,
**p < 0.01 versus vehicle control group in each time
point. n = 5 in each group.
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Adiponectin as a Downstream Effector of FGF21adiponectin (Figure 4B). Likewise, chronic administration of
recombinant FGF21 with an osmotic pump (0.5 mg/kg per day)
resulted in an approximately 5-fold elevation of circulating
FGF21 over the endogenous level (Figure 4C), and such a
change was accompanied by an 2-fold increase in plasma
levels of adiponectin (Figure 4D). Further gel filtration analysis
demonstrated that both high-molecular-weight and hexameric
adiponectin were significantly elevated after FGF21 treatment,
although themagnitude of increase in the high-molecular-weight
adiponectin was more obviously than that of the hexameric
oligomers (Figure 4E).
Adiponectin Mediates the Therapeutic Benefits of
FGF21 on Hyperglycemia and Insulin Resistance
Adipocytes play an obligatory role in conferring the pleiotropic
effects of FGF21 on glucose and lipid metabolism (Ve´niant
et al., 2012). In light of the strikingly overlapping functions
between FGF21 and adiponectin, we next investigated whether
adiponectin acts as a downstream effector mediating the acute
and/or chronic metabolic effects of FGF21 in mice. Consistent782 Cell Metabolism 17, 779–789, May 7, 2013 ª2013 Elsevier Inc.with previous reports (Berglund et al.,
2009), single injection of recombinant
FGF21 acutely decreased blood levels
of glucose, insulin, and triglyceride in
HFD-induced obese mice (Figures 5A–
5C), as well as in db/db diabetic mice
(Figure S1 available online). In ADNKO
mice with dietary and genetic obesity,
acute treatment with FGF21 was also
able to decrease glucose, insulin, and
triglycerides levels. However, the magni-
tude of FGF21-mediated decreases in
ADNKO mice was significantly lower
than those in wild-type controls, suggest-
ing that these acute metabolic effects of
FGF21 are mediated in part by adiponec-
tin. On the other hand, FGF21-inducedphosphorylation of ERK1/ERK2 in adipose tissue was compara-
ble between ADNKO mice and WT controls (Figure 5D). The ex-
pression levels of the four major types of FGF receptors (FGFR1–
FGFR4) in adipose tissues remained unchanged, whereas there
was amodest, but significant, elevation in b-klotho expression in
ADNKO mice as compared to wild-type controls (Figure S2).
We next compared the chronic effects of FGF21 in ADNKO
mice and WT littermates with diet-induced obesity using an
osmotic pump-based delivery system. Chronic treatment with
recombinant FGF21 for a period of 4 weeks caused a compara-
ble level of decrease in diet-induced body weight and fat mass
gains between WT and ADNKO mice (Figures 6A and 6B). A
glucose tolerance test demonstrated that chronic administration
of FGF21 into WT mice ameliorated HFD-induced impairment in
glucose clearance (Figure 6C). HFD-induced insulin resistance,
as determined by an insulin tolerance test, was also dramatically
attenuated by chronic FGF21 treatment (Figure 6D). At the
molecular level, such improvements in glucose clearance and in-
sulin sensitivity in FGF21-treated obesemicewere accompanied
by a significant elevation in insulin-stimulated phosphorylation of
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Figure 5. The Acute Metabolic Effects
of rmFGF21 in Mice with or without
Adiponectin
(A–C) Blood glucose levels (A), serum insulin
concentrations of insulin (B), and triglycerides (C)
were measured in HFD-fed ADNKO and WT mice
at various time points (0, 60, and 120 min) after
single injection with rmFGF21 (2mg/Kg).
(D) Representative western blots showing the
effects of acute FGF21 administration on total and
phosphorylated ERK1/ERK2 in epididymal fat. The
fat pads were collected at 1 hr after injection with
rmFGF21.
Data are presented as mean ± SEM. *p < 0.05,
**p < 0.01. n = 6 in each group. See also Figures S1
and S2.
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Adiponectin as a Downstream Effector of FGF21Akt and its downstream target, glycogen synthase kinase 3b
(GSK3b), as compared with those in vehicle-treated obese
mice (Figure 6E). By contrast, all these metabolic benefits of
chronic FGF21 administration, including alleviation of HFD-
induced glucose intolerance, insulin resistance, and impaired
insulin-evoked Akt activation in the liver, were largely abrogated
in ADNKO mice (Figure 6F).
Adiponectin Contributes to the Metabolic Benefits of
FGF21 in Both Liver and Skeletal Muscle
Since both therapeutic administration and transgenic expression
of FGF21 has been shown to improve serum lipid profiles and
alleviate fatty liver in mice and nonhuman primates (Xu et al.,
2009b; Kharitonenkov et al., 2007), we next investigated whether
such chronic effects of FGF21 are dependent on adiponectin. In
both ADNKO mice and WT controls on HFD, chronic FGF21
administration caused a similar degree of reduction in serum
levels of total cholesterol (Figure 7A). Serum levels of total triglyc-
erides in C57 WT mice were decreased by 57% after chronic
treatment with FGF21, whereas this FGF21-mediated reduction
was largely abrogated in ADNKO mice (Figure 7B).
Hematoxylin and eosin (H&E) analysis of liver sections demon-
strated that HFD-induced hepatic steatosis in C57 mice was
substantially attenuated by systemic administration of FGF21
for 4 weeks (Figure 7C), and this change was accompanied by
a marked reduction in serum levels of the liver injury markerCell Metabolism 17, 779alanine aminotransferase (ALT) (Fig-
ure 7D) and decreased expression of the
proinflammatory cytokines TNF-a and
MCP-1 (Figure 7E). By contrast, the
beneficial effects of chronic FGF21
administration on HFD-induced hepatic
steatosis, ALT elevation, and expres-
sion of proinflammatory cytokines were
largely diminished in adiponectin-
deficient mice. In WT mice, systemic
administration of FGF21 significantly
suppressed the expression of several
genes involved in lipogenesis (ACC1,
ACC2, CYP8B1, SCD1, and fatty acid
synthase; Table S1), whereas such
effects of FGF21 were abrogated inADNKO mice. By contrast, FGF21 inhibited the expression
of 3-hydroxy-3-methylglutaryl CoA reductase (a rate-limiting
enzyme of cholesterol synthesis) to a comparable level in
ADNKO mice and WT controls.
Consistent with the observations in the liver, chronic FGF21
administration significantly decreased the intramuscular triglyc-
eride accumulation and increased insulin-evoked Akt activation
in both soleus and gastrocnemius muscles and of HFD-induced
obese mice, whereas these muscular effects of FGF21 were
abrogated in ADNKO mice (Figure S3).
Adiponectin Confers the Effects of FGF21 on Hepatic
Fatty Acid Oxidation and Lipid Clearance
Chronic treatment with FGF21 had no obvious effect on food
intake in either ADNKO mice or WT controls (Figure S4A). In
WT mice chronically administered with FGF21, energy expendi-
ture (VO2) was increased, whereas the respiratory exchange
ratio (RER) was decreased, as compared to vehicle-treated
group (Figures S4B–S4D). In ADNKO mice, FGF21-induced
elevation of energy expenditure was comparable to WT mice,
whereas the magnitude of FGF21-mediated RER reduction
was significantly smaller than that in WT mice, suggesting that
FGF21-induced lipid utilization is partly dependent on adipo-
nectin. Chronic FGF21 administration decreased serum levels
of free fatty acids (FFAs) and increased serum concentrations
of b-hydroxybutyrate (Figures S5A and S5B), whereas the–789, May 7, 2013 ª2013 Elsevier Inc. 783
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Figure 6. Effects of Chronic rmFGF21
Administration on Body Weight, Fat Mass,
Glucose Metabolism, and Insulin Sensitivity
in Mice with or without Adiponectin
Four-week-old ADNKO and WT mice were fed
with HFD for 4 weeks, followed by systemic
administrationwith rmFGF21 or saline (as a vehicle
control) with osmotic pumps (0.5 mg/kg per day)
for another 4 weeks.
(A) Body weight measured weekly after treatment
(B) Fat mass measured biweekly.
(C) GTT performed at 2 weeks after rmFGF21
treatment.
(D) ITT performed at 4 weeks after rmFGF21
treatment.
(E and F) Representative immunoblots showing
phospho (Thr308) and total Akt, phospho (Ser9)
and GSK3b in the liver of WT and ADNKO mice,
respectively. The tissues were collected at 10 min
after single injection of insulin (0.5 U/kg) in mice on
HFD treated with rmFGF21 or vehicle for 2 weeks.
The bar chart under each blot is the densitometric
analysis of phosphorylation levels.
Data are presented as mean ± SEM. *p < 0.05,
**p < 0.01. n = 5 in each group. NS, not significant.
See also Figures S3–S5 and Table S1.
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Adiponectin as a Downstream Effector of FGF21amplitude of FGF21-mediated reduction in FFAs and elevation in
b-hydroxybutyrate in ADNKO mice was markedly attenuated.
The rate of [1-14C]palmitate oxidation in the liver homogenate
freshly isolated from FGF21-treated WT mice was significantly
higher than vehicle-treated controls, but this FGF21-induced
elevation was compromised in ADNKO mice (Figure S5C). Simi-784 Cell Metabolism 17, 779–789, May 7, 2013 ª2013 Elsevier Inc.larly, chronic treatment of primary hepa-
tocytes with recombinant adiponectin,
but not FGF21, increased [1-14C]palmi-
tate oxidation (Figure S5D), suggesting
that FGF21-induced hepatic fatty acid
oxidation is not due to its direct effect
on hepatocytes. In response to oral chal-
lenge with peanut oil, WT mice receiving
chronic treatment of FGF21 exhibited
significantly higher rates of lipid clear-
ance as compared to the vehicle-treated
mice. On the other hand, ADNKO mice
displayed severely impaired lipid clear-
ance under both basal and FGF21-
treated conditions when comparing to
the WT littermates (Figure S5E).
DISCUSSION
Although both pharmacological and
physiological studies in rodents and non-
human primates have demonstrated the
profound effects of FGF21 in controlling
glucose and lipid homeostasis, the un-
derlying mechanisms remain poorly char-
acterized. The tissue specificity of FGF21
actions is determined by the expressionof FGFR1 and the single-passmembrane protein b-klotho, which
have been shown to act as a receptor and coreceptor of FGF21,
respectively (Kharitonenkov et al., 2008). Adipocytes, in which
both FGFR1 and b-klotho are highly expressed, are a predomi-
nant site of FGF21 action. Data from both lipodystrophic mice
(Ve´niant et al., 2012) and adipose-specific FGFR1 (Adams
AC
D E
B Figure 7. The Beneficial Effects of Chronic
Administration with FGF21 on Dyslipidemia
and Fatty Liver Are Compromised by Adipo-
nectin Deficiency in Mice
ADNKO mice and WT mice on HFD were treated
with rmFGF21 or vehicle control for 4 weeks as in
Figure 6. Age- and sex-matched mice on Chow
were used as controls.
(A) Serum levels of triglycerides.
(B) Serum levels of total cholesterol
(C) H&E staining of liver sections.
(D) Serum levels of ALT.
(E) The mRNA expression of TNF-a and MCP-1 as
quantified by real-time PCR.
Data are presented as mean ± SEM. *p < 0.05,
**p < 0.01. n = 6 in each group. See also Figures S4
and S5 and Table S1.
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Adiponectin as a Downstream Effector of FGF21et al., 2013) and b-klotho knockout mice (Ding et al., 2012)
confirmed an obligatory role of adipocytes in FGF21-mediated
metabolic homeostasis. However, it is still unclear how FGF21
actions in adipocytes lead to profound systemic changes in
glucose and lipid metabolism. In the present study, we provide
both in vitro and animal evidence showing that FGF21 induces
the biosynthesis of adiponectin, which in turn acts in an endo-
crine manner to exert its effects on insulin sensitization and
metabolic regulation in other major metabolic organs.
Adiponectin biosynthesis in adipocytes is tightly controlled
at both the transcriptional and posttranslational levels (Wang
et al., 2008;Wang et al., 2006). In obesity, adipocyte hypertrophy
causes impaired expression and secretion of adiponectin,Cell Metabolism 17, 779thereby leading to hypoadiponectinemia,
which is an independent risk factor for
insulin resistance and diabetes (Li et al.,
2011). Therefore, therapeutic interven-
tions that augment the production of
endogenous adiponectin have been pro-
posed as a promising treatment modality
for obesity-related metabolic disorders
(Li et al., 2011). In the present study, we
showed that FGF21 increases serum
adiponectin by enhancing both its gene
transcription and protein secretion in
adipocytes. FGF21 acutely increases adi-
ponectin secretion in adipocytes and ele-
vates its circulating concentrations in
mice, both of which occur well before
transcriptional activation of the adipo-
nectin gene. On the other hand, the
amplitude of elevation in adiponectin pro-
duction by chronic infusion of FGF21,
which is associated with increased levels
of adiponectin gene expression and the
protein abundance of several molecular
chaperones involved in adiponectin olig-
omerization, is much higher than that by
acute FGF21 injection. Therefore, it is
likely that the acute effect of FGF21 is
due to its ability in stimulating adiponectinrelease via a nongenomic mechanism, whereas chronic actions
of FGF21 on sustained elevation of circulating adiponectin are
attributable to both increased gene expression and protein
secretion of adiponectin.
In obese subjects and type 2 diabetic patients, serum FGF21
levels are elevated (Zhang et al., 2008; Chen et al., 2011a),
whereas serum adiponectin levels are decreased (Weyer et al.,
2001; Lindsay et al., 2002). There are several possible mecha-
nisms that could account for the paradoxical dissociation
between serum levels of adiponectin and FGF21 in obesity and
type 2 diabetes. First, FGF21 is not the only regulator of adi-
ponectin production. Many factors that negatively regulate
adiponectin expression and secretion, such as proinflammatory–789, May 7, 2013 ª2013 Elsevier Inc. 785
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Adiponectin as a Downstream Effector of FGF21cytokines, endoplasmic reticulum stress, and oxidative stress,
are progressively increased in adipose tissues during the
development of obesity (Fasshauer et al., 2003; Liu and Liu,
2010). Therefore, elevated FGF21 is not sufficient to counteract
the effects of these negative regulators on adiponectin produc-
tion under this circumstance. This assumption is supported by
our observation that FGF21 KO mice are more susceptible to
HFD-induced reduction in serum adiponectin as compared to
WT controls. Second, FGF21 resistance in adipose tissues has
been reported in obese animals (Fisher et al., 2010; Ge et al.,
2011) and may be further aggravated by chronic inflammation
with the progression of obesity (Dı´az-Delfı´n et al., 2012). There-
fore, it is likely that the ability of FGF21 to induce adipocyte
production of adiponectin is diminished due to FGF21 resistance
in obesity and type 2 diabetes.
A recent study has demonstrated a critical role of a positive
feedback loop between FGF21 and PPARg in adipocytes in
maintaining systemic glucose homeostasis (Dutchak et al.,
2012). The autocrine actions of FGF21 activate PPARg, which
in turn leads to further induction of FGF21 expression via tran-
scriptional activation. Our present study demonstrated that
both the acute and chronic effects of FGF21 on adiponectin pro-
duction are mediated in part by PPARg, a nuclear receptor that
controls the gene transcription as well as the protein secretion
of adiponectin (Wang et al., 2007; Iwaki et al., 2003). Further-
more, we found that the stimulatory effects of the PPARg ago-
nists TZDs on adiponectin production in both mouse adipocytes
and human adipose tissue are mediated by augmented auto-
crine actions of FGF21. Taken together, these findings suggest
that TZDs exert their antidiabetic actions by amplifying the
autocrine signal of FGF21 in adipocytes, which consequently
triggers the release of adiponectin into the bloodstream for
alleviation of peripheral insulin resistance (Figure S3). In support
of this notion, both FGF21 and ADNKOmice are refractory to the
therapeutic benefits of TZDs on insulin sensitivity and glucose
homeostasis (Dutchak et al., 2012; Nawrocki et al., 2006; Ku-
bota et al., 2006).
FGF21 has been shown to exert multiple metabolic effects in
the liver, including alleviation of diet-induced hepatic insulin
resistance and hepatic steatosis (Xu et al., 2009b) and regulating
hepatic gluconeogenesis and ketogenesis (Potthoff et al., 2009;
Badman et al., 2007). However, whether liver is the direct target
of FGF21 remains debatable (Potthoff et al., 2009; Fisher et al.,
2011). Hepatocytes express b-klotho but not FGFR1, the latter
of which is a major receptor isoform for FGF21 (Suzuki et al.,
2008). In vivo administration of FGF21 enhances hepatic fatty
acid oxidation and tricarboxylic acid cycle flux via inducing the
expression of PGC1a and its downstream target genes (Potthoff
et al., 2009). By contrast, direct incubation of either isolated
mouse liver or primary cultures of rat hepatocytes with FGF21
has no such effects, implicating that FGF21 exerts these hepatic
actions via an indirect mechanism that may involve other secre-
tory factors. In line with these findings, our present study sug-
gests adiponectin to be an obligatory mediator for these hepatic
actions of FGF21. This notion is supported by our observation
that the chronic effects of FGF21 on alleviation of diet-induced
hepatic insulin resistance, steatosis, and liver injury are abol-
ished in ADNKO mice. Indeed, hepatocytes are the direct target
of adiponectin, where this adipokine inhibits fatty acid synthesis,786 Cell Metabolism 17, 779–789, May 7, 2013 ª2013 Elsevier Inc.enhances fatty acid oxidation, and increases insulin sensitivity
(Berg et al., 2001; Xu et al., 2003). Likewise, the lack of responses
to FGF21-mediated lipid depletion and insulin sensitization in
skeletal muscle of ADNKOmice also suggests that the muscular
effects of chronic FGF21 administration are also mediated by
adiponectin, but not due to the direction action of FGF21 in
this tissue.
While the metabolic effects of chronic FGF21 administration
on liver and skeletal muscle are largely abolished by adiponectin
deficiency, it is of interest to note that its activities in adipose
tissue, including activation of ERK1/ERK2 and reduction of fat
mass, remain intact. In adipocytes, FGF21-mediated activation
of ERK1/ERK2 leads to the induction of glucose transporter-1
expression, thereby enhancing insulin-independent glucose
uptake (Ge et al., 2011; Kharitonenkov et al., 2005). Since
pharmacological inhibition of ERK1/ERK2 has no obvious effect
on FGF21-induced adiponectin production in adipocytes, this
kinase does not appear to be an important player in mediating
the systemic effects of FGF21 on glucose metabolism and insu-
lin sensitivity. FGF21-mediated fat mass loss has been attrib-
uted to its ability in enhancing energy expenditure (Coskun
et al., 2008), possibly resultant from increased transdifferentia-
tion of white to brown adipocytes (Potthoff et al., 2012). While
our present study showed a comparable degree of FGF21-
mediated reduction of diet-induced obesity between ADNKO
mice and WT controls, such a beneficial effect of FGF21 is
compromised in mice with adipose tissue selective depletion
of either FGFR1 or b-klotho (Adams et al., 2013; Yang et al.,
2012). Taken together, these findings suggest that the reduction
of fat mass by FGF21 is a consequence of its direct actions
in adipocytes, independent of adiponectin. Indeed, unlike
FGF21 transgenic mice resistant to diet-induced obesity (Ina-
gaki et al., 2007), transgenic expression of adiponectin causes
morbid obesity despite a healthy metabolic profile (Kim et al.,
2007), highlighting the differences between these two factors
in regulating adiposity.
Another notable observation of the present study is that adipo-
nectin deficiency leads to a compromised effect of FGF21
on suppression of HFD-induced hypertriglyceridemia, but not
hypercholesterolemia. In line with our findings, a recent study
on lipodystrophic mice demonstrated that adipose tissue is
obligatory in mediating the triglyceride-lowering effects of
FGF21 but is not required for its cholesterol-lowering activities
(Ve´niant et al., 2012). Therefore, it is likely that the beneficial
effects of FGF21 on hypertriglyceridemia are attributable to its
ability in facilitating fatty acid combustion in both liver and
skeletal muscle, whereas FGF21-mediated reduction of hyper-
cholesterolemia is independent of its actions on adipocytes
and does not require adiponectin. In support of this notion,
adiponectin has been reported to decrease circulating levels of
triglycerides, but not cholesterol (Yamauchi et al., 2001).
In summary, our present study has demonstrated a central
role of adiponectin in conferring the therapeutic benefits of
FGF21 in improving obesity-induced hyperglycemia, hypertrigly-
ceridemia, and peripheral insulin resistance. These findings
provide a molecular mechanism to explain how FGF21, via its
actions in adipocytes, controls systemic glucose and lipid
homeostasis and insulin sensitivity in the major metabolic
organs.
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Animals
Male FGF21 KO mice (Hotta et al., 2009), ADNKO mice (Ma et al., 2002),
PPARg heterozygous-deficient mice (Ppargtm3Yba/Pparg+, Jackson labora-
tory, PPAR+/), leptin receptor/ (db/db) mice and leptin receptor//
adiponectin/ double knockout (DKO) mice (Zhou et al., 2008) with a
C57BL/6J background, and WT controls with the same genetic backgroup
were used for this study. These mice were fed with either standard chow or
an HFD diet (D12451, Research Diet, New Brunswick, NJ) containing 45%
fat, 20% protein, and 35% carbohydrate (kcal%). All animals were kept under
12 hr light-dark cycles at 22C –24C, with free access to water. Glucose toler-
ance and insulin tolerance tests were conducted as we previously described
(Xu et al., 2009a). All of the experiments were conducted under our institutional
guidelines for the humane treatment of laboratory animals.
Metabolic Effects of rmFGF21
rmFGF21 and rabbit anti-human FGF21 IgG were prepared as described pre-
viously (Yu et al., 2011; Ge et al., 2011). For the acute studies, 12-week-old
mice were injected intraperitoneally with either rmFGF21 (2 mg/kg) or saline
as vehicle control. Blood samples were collected at various time points after
injection for measurement of glucose, triglycerides, and cholesterol as
described (Xu et al., 2009a). For chronic studies, 8-week-old ADNKO mice
or WT controls which had been on HFD for 4 weeks were implanted with an
Alzet osmotic pump as described previously (Xu et al., 2003), to continuously
deliver rmFGF21 for 4 weeks (0.5 mg/kg per day). Glucose and insulin
tolerance tests were performed 2 and 3 weeks after treatment, respectively.
Total fat and lean mass was quantified with a Brucker Minispec Body compo-
sition analyzer. Mice were sacrificed after 4 weeks of treatments for collection
of various tissues for further biochemical and histological evaluations.
Differentiation of Mouse Adipocytes
Stromal vascular cells were isolated from epididymal fat pads of 8-week-old
FGF21 KO mice or WT controls by collagenase digestion and centrifugation
and were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum. Differentiation was initiated as described
(Xu et al., 2009a). Ten days after differentiation, more than 80% of cells
became mature adipocytes filled with multiple lipid droplets as assessed by
oil red O staining.
Pulse-Chase Experiment with 35S-LabeledMethionine and Cysteine
Pulse-chase experiment with 35S-labeled methionine and cysteine were per-
formed as described (Xu et al., 2009a). In brief, mouse adipocytes were
starved in methionine- and cysteine-free DMEM for 1 hr and were then incu-
bated with the same fresh medium plus 50 mCi/ml [35S]methionine and [35S]
cysteine (Redivue Pro-mix L-[35S]; GEHealthcare, Piscataway, NJ) for another
1 hr. The medium was replaced subsequently with cold DMEM with a 20-fold
excess of methionine and cysteine for different time periods. Both the culture
medium and cells were harvested for immunoprecipitationwith affinity-purified
rabbit anti-mouse adiponectin IgG as described (Xu et al., 2005). The immuno-
precipitated complexes were eluted by incubation with a SDS-PAGE loading
buffer. The eluted samples were separated by 15% gradient SDS-PAGE and
then analyzed by phosphorimaging (BAS 2000; Fujifilm, Tokyo, Japan).
Ex Vivo Studies with Human Adipose Tissue Explants
Human subcutaneous fat tissues were obtained from five healthy premeno-
pausal Chinese women undergoing abdominal surgery for benign gynecolog-
ical conditions and minced into small pieces. The fat explants were cultured in
DMEM medium with 0.5% BSA for 30 min and were then treated with rosigli-
tazone and in the presence of 2 mg/ml rabbit anti-human FGF21 antibody (Yu
et al., 2011) or nonimmune IgG for 24 hr. The conditioned medium and cells
were collected to quantify the protein secretion and mRNA expression of
adiponectin. All subjects gave informed consent, and all the procedures
were approved by the local ethics committee.
Biochemical and Immunological Assays
Serum ALT activities were determined with a commercial kit from Sigma-
Aldrich (St. Louis, MO). Serum levels of insulin, total adiponectin, and FGF21Cwere quantified with immunoassays from Antibody and Immunoassay
Services at University of Hong Kong. Different oligomeric forms of adiponectin
in serum samples were analyzed by gel filtration as described (Xu et al., 2005).
Serum FFA and b-hydroxybutyrate concentrations were measured with the
Free Fatty Acids, Half Micro Test (Roche) and b-hydroxybutyrate Assay Kit
(Abcam), respectively.
Immunoblotting and Histological Analysis
Proteins were extracted from liver tissues in the presence of protease inhibi-
tors cocktail (Roche Applied Science), resolved by SDS-PAGE, and then trans-
ferred to PVDF membranes. The membranes were then probed with primary
antibodies against Ero1-La (Santa Cruz Biotechnology), phospho-Akt, Akt,
phosphor-GSK3b, GSK3b (Cell Signaling Technology), and DsbA-L (Abcam)
followed by incubation with corresponding horseradish peroxidase-conju-
gated secondary antibodies. The protein bands were visualizedwith enhanced
chemiluminescence reagents (GE Healthcare, Uppsala, Sweden) and quanti-
fied with the NIH Image J software.
Liver specimens were fixed in 10% formalin solution (Sigma) and embedded
in paraffin. Liver tissue sections were stained with H&E via standard proce-
dures. All slides were examined under Olympus biological microscope
BX41, and images were captured with an Olympus DP72 color digital camera.
RNA Extraction and Real-Time PCR
Total RNA was extracted from liver or adipose tissues with TRIzol reagent
(Invitrogen), and complementary DNA was synthesized from 0.5 mg total
RNA by reverse transcription with an ImProm-II reverse transcription kit
(Promega) with random hexamer primers. Quantitative real-time PCR was
performed through the use of the SYBR Green QPCR system (QIAGEN) with
specific primers (Table S2). The PCR reactions were performed with an
Applied Biosystems Prism 7000 sequence detection system. The level of
target gene expression was normalized against the GAPDH gene.
Statistical Analysis
Experiments were performed routinely with five to six mice per group. All
analyses were performed with Statistical Package for Social Sciences version
14.0 (SPSS, Chicago, IL). Data were expressed as mean ± SEM. Comparison
between groups was performed via ANOVA followed by Bonferroni correction
in the case of multiple comparisons. In all statistical comparisons, a p value <
0.05 was used to indicate a statistically significance difference.
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